不良事件报告

如果发生不良事件,患者应始终寻求医生或药剂师的建议。

如果您想向ELC Group s.r.o.报告不良事件,请在下面找到联系信息:

+420 224 910 672

(欧洲中部时间09.00-17.30)

+420 226 251 459

(24/7不间断)

有关其他任何问题,请与我们联系:

+420 22 491 0000或我们的 区域办事处。

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

Full software solution plus specialist support services offers pharmaceutical Marketing Authorisation Holders fastest route to meeting XEVMPD mandate

Cambridge, UK, February 21 2012 – ELC Group, the pan-European pharmaceutical regulatory affairs organisation, today announces the launch of a new subsidiary, Pharma eReport – a software and services company that delivers a comprehensive EVMPD compliance solution for pharmaceutical regulatory professionals.

Pharma eReport offers a total package for Marketing Authorisation Holders (MAHs) seeking to meet the July 2nd 2012 deadline for mandatory EudraVigilance Medicinal Product Dictionary (EVMPD/XEVMPD) data submissions. With its flagship Centrality software suite and specialist EVMPD services – delivered by a Key Support Services team of qualified chemists – Pharma eReport provides a comprehensive EVMPD solution, including complete outsourced data-gathering and compilation of Structured Substance Information (SSI) libraries. The Centrality software is available as an on-demand software-as-a-service (SaaS)/cloud-based solution – accessed via a standard web browser – or it can be installed as a standalone software application. Centrality is offered via a transparent pricing model and will be in full general availability from March 2012. Prospective users are invited to sign up online now for priority product demonstrations.

Pharma eReport’s Centrality software tool allows MAHs to quickly and effortlessly convert existing medicinal product information into an XML Schema Definition (XSD)- compliant format, and seamlessly upload the required data as a EudraVigilance Product Report Message (EVPRM) using an approved submission mechanism. The software is secure, easy to use and custom-engineered for flexible implementation, including development support for bespoke interfaces to provide full harmonisation with customers’ existing systems.

Pharma eReport’s Centrality platform provides an intuitive product license management system for database-wide pharmacovigilance updates, tracking, organising and managing product and substance information, and ensuring continuing EMA regulatory compliance. Centrality can be coupled with specialist Key Support Services – including data collation, organisation and mapping capabilities, plus complete SSI library compilation services – to enable customers to extract maximum value from substance data.

Pharma eReport is co-founded by the management of ELC Group plus former executives from electronic design automation software company Synopsys, Inc. Pharma eReport harnesses the unparalleled industry knowledge of its regulatory expert founders and combines this with a world-class software development team to deliver a total solution for EVMPD compliance and beyond.

Commenting on the solution launch, Marco Rubinstein, CEO of ELC Group and Pharma eReport said: “We are launching our new subsidiary and the Centrality solution to deliver the full service solution that regulatory teams need to meet the time-critical EVMPD compliance challenge. We’ve designed a uniquely flexible, transparently-priced software solution which can be supported by our highly skilled service organisation of qualified chemists and, crucially, access to our key SSI library resources. For regulatory teams, we are reducing the admin burden and providing an easy-to-use software platform that creates a valuable centralised product license and information database for future use.” He continued: “Beyond the immediate 2012 deadline, all MAH submissions will soon need to comply with a coming ISO IDMP (Identification of Medicinal Products) standard, expected to be in force by 2015. So pharmaceutical companies that are selling or marketing medicinal products in Europe will need to implement an effective e-reporting solution now, to reduce the MAH submissions management overhead and ensure seamless ongoing regulatory adherence. We’re looking forward to becoming the industry’s key solution partner for EVMPD compliance – and beyond.”

To sign up online for a priority demonstration, please visit: http://www.pharmaereport.com

相关新闻